Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by enriquesuaveon Dec 20, 2020 3:24pm
349 Views
Post# 32149602

End Points

End Points The Primary end point is CR at any time point. The Secondary  endpoint is duration of CR status which is how long patient remains CR up to 365 days after CR was first determined.  Tertiary endpoint of safety or adverse events.  IMO most patients who are CR should be determined at day 30 or 90 depending on whether they do a cystoscope exam at 30 days as well as 90 days as well as urine cytology. It would seem that any patient who is determined to be CR at 30 days, then that would probably be the result of a complete tumor destruction. Anyone who would maybe be CR at 90 but not at 30 days would maybe be complete destruction only after development of an immune response after partial tumor destruction by PDT. All imo. I'm pretty sure they are doing cystoscope exams at day 30 as well. 2021 could and hopefully will be our best year ever to date. All imo
<< Previous
Bullboard Posts
Next >>